Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Other Income/Expenses (Net) Over TimeExpanding
Percentile Rank100
3Y CAGR+276.2%
Year-over-Year Change
Net other income and expenses outside core operations
3Y CAGR
+276.2%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
53.2x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $3.96M | +270.7% |
| 2024 | $1.07M | +0.8% |
| 2023 | $1.06M | +1324.9% |
| 2022 | $74453.00 | +473.7% |
| 2021 | $-19923.00 | +32.2% |
| 2020 | $-29402.00 | -18.4% |
| 2019 | $-24835.00 | +18.1% |
| 2018 | $-30332.00 | +2.0% |
| 2017 | $-30945.00 | -100.3% |
| 2016 | $-15449.00 | - |